Crescent Biopharma, Inc.
CBIO
$10.60
$0.252.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Net Income | -275.49% | -12.93% | |||
| Total Depreciation and Amortization | 92.86% | 1,300.00% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 3,978.85% | -72.44% | |||
| Change in Net Operating Assets | -487.84% | 329.63% | |||
| Cash from Operations | -52.46% | -6.93% | |||
| Capital Expenditure | 67.06% | -318.57% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | -- | |||
| Cash from Investing | -12,219.62% | -318.57% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | 100.00% | -608.47% | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -100.00% | |||
| Cash from Financing | 14,363.16% | -100.85% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 512.44% | -114.87% | |||